AcelRx to resubmit NDA in 2015 By: MarketMinute.com Stock News September 26, 2014 at 13:52 PM EDT AcelRx Pharmaceuticals Inc. (Nasdaq: ACRX) will resubmit its New Drug Application for Zalviso in the first quarter of 2015. The stock price tumbled $1.23 to $5.49. Related Stocks: Acelrx Pharmaceutica